Eyepoint Pharmac SEC Filings

EyePoint Pharmaceuticals (EYPT) reported an insider transaction by its Chief Medical Officer. On 11/11/2025, the officer sold 2,722 shares of common stock in open market transactions at a weighted average price of $11.61. The filing states these shares were originally acquired on January 31, 2025 under the company’s 2019 Employee Stock Purchase Plan. Following the sale, the filing lists 0.00 shares beneficially owned, reported as Direct (D) ownership.

EyePoint Pharmaceuticals filed a prospectus supplement covering the registered offering of up to $200,000,000 of common stock pursuant to its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. The supplement relates to the company’s effective Form S-3 (File No. 333-290867), which became automatically effective upon filing.

The company also filed a legal opinion from Hogan Lovells US LLP validating the Shares, included as Exhibit 5.1. This filing provides a framework to sell shares as needed under the existing sales agreement, offering flexibility to access capital subject to market conditions.

EyePoint Pharmaceuticals (EYPT) launched an at-the-market offering of up to $200,000,000 in common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald. Shares may be sold from time to time in transactions deemed “at the market offerings” under Rule 415(a)(4), including sales on The Nasdaq Global Market. Cantor will act as sales agent and receive a fixed commission equal to 3.0% of the aggregate gross sales price per share sold.

The company states it intends to use net proceeds to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs leveraging its Durasert E technology, and for general corporate purposes. The common stock trades on Nasdaq under “EYPT”; the last reported sale price was $12.45 on November 3, 2025.

EyePoint Pharmaceuticals (EYPT) reported a wider Q3 loss as it advances late‑stage trials. Total revenue was $0.97 million, down 91% year over year, mainly due to prior deferral recognition tied to YUTIQ® licensing. Research and development rose to $47.8 million (up 62%) as Phase 3 wet AMD studies (LUGANO, LUCIA) continued. Net loss was $59.7 million, or $0.85 per share.

Cash, cash equivalents and marketable securities were $204.0 million as of September 30, 2025. After quarter‑end, the company closed an underwritten equity offering with net proceeds of approximately $162.1 million and sold additional shares via its ATM. Management states these resources are expected to fund operations into the fourth quarter of 2027, beyond anticipated 2026 topline data for DURAVYU™.

Deferred revenue from the ANI YUTIQ® arrangement was fully recognized by Q2 2025, reducing current‑period license revenue. The company recorded a $4.7 million accrual for a potential DOJ matter resolution. Shares outstanding were 82,787,220 as of October 30, 2025.

EyePoint Pharmaceuticals (EYPT)Exhibit 99.1.

This is a routine disclosure that makes the quarter’s results available through the attached exhibit. EYPT’s common stock trades on the Nasdaq Global Market under the symbol EYPT.

EyePoint Pharmaceuticals completed an underwritten public offering of 11,000,000 shares of common stock at $12.00 per share and pre-funded warrants to purchase 1,500,000 shares at $11.999 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 1,875,000 shares at the same price.

The company received approximately $141 million in net proceeds after underwriting discounts and commissions, and the offering closed on October 16, 2025. EyePoint plans to use the proceeds to advance clinical development of DURAVYU for wet age‑related macular degeneration and diabetic macular edema, support earlier‑stage pipeline initiatives, and for general corporate purposes.

The pre‑funded warrants are exercisable at any time, do not expire, carry a $0.001 per share exercise price, and include beneficial ownership limits of 4.99% or 9.99% at the holder’s election, adjustable up to 19.99% with 61 days’ notice.

EyePoint Pharmaceuticals launched a primary offering of 11,000,000 shares of common stock and pre-funded warrants for 1,500,000 shares at $12.00 per share and $11.999 per warrant.

The deal is expected to generate approximately $140.7 million in net proceeds, with a 30-day option for underwriters to purchase up to 1,875,000 additional shares. Management plans to use the funds to advance Phase 3 development of DURAVYU for wet AMD and DME, support earlier-stage programs, and for general corporate purposes. The company states these resources, together with existing cash, are expected to fund operations into the fourth quarter of 2027, beyond anticipated wet AMD topline data in 2026.

The pre-funded warrants carry a $0.001 exercise price and may be exercised for shares; there will be no public market for these warrants.

EyePoint Pharmaceuticals (EYPT) launched a primary offering of $150,000,000 of common stock via a prospectus supplement, with underwriters granted a 30‑day option to purchase up to an additional $22,500,000 at the public offering price, less underwriting discounts and commissions.

The company’s common stock trades on Nasdaq Global Market under “EYPT.” Estimated net proceeds are intended to advance clinical development of DURAVYU for wet AMD and DME, support earlier-stage pipeline programs, and for general corporate purposes. EyePoint estimated approximately $200 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company states that existing cash plus expected net proceeds should fund operations into the fourth quarter of 2027.

Recent updates note DURAVYU’s Phase 3 program initiation planning in DME and ongoing Phase 3 trials in wet AMD. As context, shares outstanding were 68,889,649 as of June 30, 2025, plus 825,844 shares issued under an at‑the‑market program through October 6, 2025. A 60‑day lock‑up applies to the company and insiders, with specified exceptions.

EyePoint Pharmaceuticals (EYPT) filed an 8-K noting two updates. The company posted an investor presentation that includes estimated cash and investments as of September 30, 2025. These figures were calculated before review by the independent registered public accounting firm and are subject to change upon completion of the quarterly report for the period ended September 30, 2025.

EyePoint also announced details for its pivotal Phase 3 program evaluating DURAVYU (vorolanib intravitreal insert) for diabetic macular edema, with first patient dosing anticipated in Q1 2026. The press release and presentation were made available on the company’s website.